Is a complete PLYX research report available?

No complete published report is available for Polaryx Therapeutics, Inc. (PLYX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Polaryx Therapeutics, Inc. (PLYX)

NASDAQ: PLYX · USD

$2.15

+0.16 (+8.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first PLYX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	101.8M
Net income (ttm)	-6.5M
EPS (ttm)	-$0.14
Shares out	47.3M
Volume	127,834
Price target	$8.50	+295.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -6.5M
EPS (ttm): -$0.14
Market cap: 101.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All PLYX indicators

Market & fundamental data

Available fields

144

Groups with data

Currency

USD

Showing 144 of 144 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002075320
Company name	Polaryx Therapeutics, Inc.
Country	United States
Country code	US
Cusip	73110F100
Employees	11
Enterprise value	$101.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US73110F1003
Last refreshed	2026-07-31
Market cap	$101.8M
Market cap category	Micro-Cap
Price	$2.15
Price currency	USD
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	PLYX
Website	https://polaryx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.22%
P/B ratio	41.86x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-6.5M
Net Income Growth Years	1%
Profit Per Employee	$-588,818
ROA	-74.42
ROCE	-190
ROE	-192.2
ROIC	-87.65

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$3.5M
Cash	$3.1M
Current Assets	$3.5M
Current Liabilities	$1M
Debt	$0
Equity	$2.5M
Liabilities	$1M
Long Term Assets	$0
Long Term Liabilities	$0
Net Cash	$3.1M
Net Cash By Market Cap	$2.96
Net Cash Growth	-26%
Net Debt Equity	$-1.24
Tangible Book Value	$2.5M
Tangible Book Value Per Share	$0.05

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.45
Net Working Capital	$-592,000
Quick ratio	3.04
Working Capital	$2.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-17.84%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	2.5
All Time High	48.91
All Time High Change	-95.6%
All Time High Date	2026-02-02
All Time Low	1.86
All Time Low Change	15.59%
All Time Low Date	2026-07-28
ATR	0.24
Beta1y	-2.07
High	2.2
High52	48.91
High52 Date	2026-02-02
High52ch	-95.6%
Low	1.97
Low52	1.86
Low52 Date	2026-07-28
Low52ch	15.59%
Ma50ch	-13.83%
Premarket Change Percent	-2.01
Premarket Price	$1.95
Premarket Volume	8,523
RSI	42.69
RSI Monthly	0
RSI Weekly	37.43
Sharpe ratio	-1.35x
Sortino ratio	-1.97
Total Return	-17.84%
Tr1m	-15.02%
Tr1w	1.9%
Tr3m	-58.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.03
Operating Income	$-4.7M
Price target	$8.5
Price Target Change	$295

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4,275,083%
Float Percent	9.03%
Shares Insiders	33.33%
Shares Institutions	5.03%
Shares Out	47,343,297
Shares Qo Q	0.74%
Shares Yo Y	17.84%
Short Float	7.17%
Short Ratio	2.87
Short Shares	0.65

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted OCF	-6,039,000
Average Volume	100,038.95x
Bv Per Share	0.05
Ch1m	-15.02
Ch1w	1.9
Ch3m	-58.81
Change	8.04%
Change From Open	6.44
Close	1.99
Days Gap	1.51
Dollar Volume	274,843.1
Earnings Date	2026-08-14
Earnings Time	bmo
EBIT	$-4.7M
EBITDA	$-4.7M
EPS	$-0.14
F Score	1
Financing CF	4,216,000
Fiscal Year End	December
Founded	2,014
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-24
Ma20	2.29
Ma20ch	-6.2%
Net CF	-1,082,000
Next Earnings Date	2026-08-14
Open	2.02
Optionable	No
Position In Range	78.26
Post Close	2.15
Postmarket Change Percent	1.64
Postmarket Price	$2.19
Pre Close	1.99
Price Date	2026-07-30
Ptbv Ratio	41.86
Relative Volume	1.28x
Share Based Comp	741,000
Us State	New Jersey
Volume	127,834

Polaryx Therapeutics, Inc. (PLYX)

Coverage state: Market snapshot only — no published research

Generate the first PLYX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · PLYX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PLYX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on PLYX

Frequently asked questions